Apellis Pharmaceuticals. has filed a patent for methods of treating eye disorders, specifically age-related macular degeneration, using a C3 inhibitor. The treatment involves administering the inhibitor to reduce the risk of developing retinal pigment epithelium and outer retinal atrophy. GlobalData’s report on Apellis Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Apellis Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Apellis Pharmaceuticals, Cyclosporin derivatives was a key innovation area identified from patents. Apellis Pharmaceuticals's grant share as of January 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of eye disorders using c3 inhibitor

Source: United States Patent and Trademark Office (USPTO). Credit: Apellis Pharmaceuticals Inc

A patent application (Publication Number: US20230381269A1) describes a method for treating a subject with drusen in the eye to reduce the risk of developing incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) and/or complete retinal pigment epithelium and outer retinal atrophy (cRORA). The method involves administering a C3 inhibitor to the eye, detecting drusen, assessing for signs of iRORA or cRORA, and determining the presence of these conditions using optical coherence tomography. The C3 inhibitor is administered for at least 6 months, with the goal of preventing the development of iRORA and cRORA in subjects with early or intermediate age-related macular degeneration.

Furthermore, the patent application details variations in the method, including specific criteria for determining iRORA and cRORA, the administration of the C3 inhibitor via intravitreal injection, and the use of a compstatin analog as the C3 inhibitor. The compstatin analog may include a clearance-reducing moiety, such as polyethylene glycol, attached to one or more compstatin analog moieties. The method aims to slow or prevent the development of iRORA and cRORA for an extended period after starting the treatment regimen, with the potential for long-term benefits in subjects with drusen and early signs of macular degeneration. Trehalose may also be included in the C3 inhibitor composition, administered at a specific dose range to achieve the desired therapeutic effect.

To know more about GlobalData’s detailed insights on Apellis Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies